Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 8/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210718 | 1.00 | MAP4K1 (0.48) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL29906836 | 0.89 | MAP4K1 (0.54) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL23210744 | 0.89 | MAP4K1 (0.54) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL29906977 | 0.85 | MAP4K1 (0.53) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL23210924 | 0.85 | MAP4K1 (0.53) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL23210991 | 0.85 | MAP4K1 (0.46) | MAP4K1FGFR3AXLPIM1FGFR1 | |
| SCHEMBL29906904 | 0.85 | MAP4K1 (0.46) | MAP4K1FGFR3AXLPIM1FGFR1 | |
| SCHEMBL23210831 | 0.83 | MAP4K1 (0.49) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL29906967 | 0.83 | MAP4K1 (0.49) | MAP4K1FGFR3AXLMAPK1PIM1 | |
| SCHEMBL23210647 | 0.76 | MAP4K1 (0.48) | MAP4K1FGFR3AXLMAPK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | claimed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAP4K1 1403/4885FGFR3 2/4885AXL 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.